A new market research report by Transparency Market Research, titled “Neurofibromatosis Treatment Market - Global Industry Analysis, Size, Share, Growth Trends and Forecast 2015 – 2023,” provides a comprehensive understanding of the market on the basis of both revenue as well as volume.

The market competition has been encapsulated by a detailed explanation of the Porter’s five forces model. The report also presents an extensive evaluation of the macro-economic indicators, governing factors, and the major market trends. In addition, the market attractiveness of each of the segments present in the market for neurofibromatosis treatment also forms a key part of this study.

Neurofibromatosis refers to numerous genetically inherited conditions that differ genetically and clinically and carry the risk of tumor formation. These tumors may form anywhere within the nervous system of the patient including the spinal cord, nerves, or brain. In the majority of the cases, these tumors are non-cancerous.

However, in some cases, these tumors may become malignant. There are mild symptoms experienced by patients suffering from neurofibromatosis. These may include learning impairment, hearing loss, severe pain, and loss of vision, among others. There is currently no proven treatment for curing neurofibromatosis; however, there are treatments for managing the complications associated with this condition.

As per the report, the growing count of drugs in clinical trials, poised to emerge as breakthrough treatment options for this condition, are amongst the key factors fuelling the growth of the neurofibromatosis treatment market. Neurofibromatosis is of three main types, namely, neurofibromatosis type 1 (NF1), neurofibromatosis type 2 (NF2), and schwannomatosis. Amongst these, neurofibromatosis type 2 (NF2) is the most common type, whereas schwannomatosis has been recently identified and is a rare type of neurofibromatosis.

Brochure Download: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=7156

By treatment, the market is segmented into surgery, drug therapy, chemotherapy, and radiation therapy. Amongst these, surgery is the most commonly utilized option for removing tumors. Surgery is also utilized in the treatment for retinal abnormalities and cataracts in patients suffering from neurofibromatosis. However, surgeries may cause hearing impairment in patients. On the other hand, treatments such as chemotherapy and radiation therapy have also been utilized extensively in the market.

Although, at present, there are no drugs in the market, there are certain drugs in phase III of clinical trials. These are Tamsulosin HCL (GL Pharm Tech Corporation) and Lamotrigine (Erasmus Medical Center). On the other hand, the drugs in phase II of clinical trials are RAD001 (Assistance Publique - Hôpitaux de Paris), Cabozantinib (University of Alabama at Birmingham), Everolimus (Texas Neurofibromatosis Foundation), Gleevec (Indiana University), and others.

From the geographical standpoint, neurofibromatosis has a low prevalence rate and is an orphan disease. The key institutes and organizations taking efforts for the treatment of neurofibromatosis are GL Pharm Tech Corporation, Erasmus Medical Center, University of Alabama at Birmingham, Texas Neurofibromatosis Foundation, Indiana University, and Assistance Publique - Hôpitaux de Paris, among others.

Browse Full Research Report: http://www.transparencymarketresearch.com/neurofibromatosis-treatment-market.html

About Us
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.